128 related articles for article (PubMed ID: 28882511)
1. [Doses to organs at risk for conformational and stereotactic radiotherapy: Bladder].
Duvergé L; Castelli J; Lizée T; de Crevoisier R; Azria D
Cancer Radiother; 2017 Oct; 21(6-7):597-603. PubMed ID: 28882511
[TBL] [Abstract][Full Text] [Related]
2. [Dose constraints to organs at risk for conformational and stereotactic radiotherapy: Small bowel and duodenum].
Goupy F; Chajon E; Castelli J; Le Prisé É; Duvergé L; Jaksic N; Vogin G; Monpetit É; Klein V; de Bosschère L; Maingon P
Cancer Radiother; 2017 Oct; 21(6-7):613-618. PubMed ID: 28886980
[TBL] [Abstract][Full Text] [Related]
3. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
[TBL] [Abstract][Full Text] [Related]
4. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
[TBL] [Abstract][Full Text] [Related]
5. [Hippocampus, brainstem and brain dose-volume constraints for fractionated 3-D radiotherapy and for stereotactic radiation therapy: Limits and perspectives].
Gérard M; Jumeau R; Pichon B; Biau J; Blais E; Horion J; Noël G
Cancer Radiother; 2017 Oct; 21(6-7):636-647. PubMed ID: 28893524
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
7. Intensity-modulated whole pelvic radiotherapy provides effective dosimetric outcomes for cervical cancer treatment with lower toxicities.
Lv Y; Wang F; Yang L; Sun G
Cancer Radiother; 2014 Dec; 18(8):745-52. PubMed ID: 25451672
[TBL] [Abstract][Full Text] [Related]
8. [Doses to organs at risk in conformational radiotherapy and stereotaxic irradiation: The heart].
Vandendorpe B; Servagi Vernat S; Ramiandrisoa F; Bazire L; Kirova YM
Cancer Radiother; 2017 Oct; 21(6-7):626-635. PubMed ID: 28867460
[TBL] [Abstract][Full Text] [Related]
9. Organs at risk radiation dose constraints.
Noël G; Antoni D
Cancer Radiother; 2022; 26(1-2):59-75. PubMed ID: 34953713
[TBL] [Abstract][Full Text] [Related]
10. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Tong M; Wu B; Lei S; Obayomi-Davies O; Chen LN; Suy S; Dritschilo A; Yorke E; Collins SP
Acta Oncol; 2016; 55(1):52-8. PubMed ID: 25972264
[TBL] [Abstract][Full Text] [Related]
11. Predicting rectal and bladder overdose during the course of prostate radiotherapy using dose-volume data from initial treatment fractions.
Murthy V; Shukla P; Adurkar P; Master Z; Mahantshetty U; Shrivastava S
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):119-24. PubMed ID: 22300567
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous integrated protection : A new concept for high-precision radiation therapy.
Brunner TB; Nestle U; Adebahr S; Gkika E; Wiehle R; Baltas D; Grosu AL
Strahlenther Onkol; 2016 Dec; 192(12):886-894. PubMed ID: 27757502
[TBL] [Abstract][Full Text] [Related]
13. [Doses to organs at risk in conformational and stereotactic body radiation therapy: Liver].
Debbi K; Janoray G; Scher N; Deutsch É; Mornex F
Cancer Radiother; 2017 Oct; 21(6-7):604-612. PubMed ID: 28893525
[TBL] [Abstract][Full Text] [Related]
14. [Stereotactic body radiation therapy for hepatic malignancies: Organs at risk, uncertainties margins, doses].
Lacornerie T; Rio E; Mahé MA
Cancer Radiother; 2017 Oct; 21(6-7):574-579. PubMed ID: 28844506
[TBL] [Abstract][Full Text] [Related]
15. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
[TBL] [Abstract][Full Text] [Related]
16. Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review.
Clemente S; Nigro R; Oliviero C; Marchioni C; Esposito M; Giglioli FR; Mancosu P; Marino C; Russo S; Stasi M; Strigari L; Veronese I; Landoni V
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):182-95. PubMed ID: 25835624
[TBL] [Abstract][Full Text] [Related]
17. [Hepatic tumors and radiotherapy].
Rio E; Mornex F; Peiffert D; Huertas A
Cancer Radiother; 2016 Sep; 20 Suppl():S174-8. PubMed ID: 27521035
[TBL] [Abstract][Full Text] [Related]
18. [Normal tissue tolerance to external beam radiation therapy: Bone marrow and cortical bone structures].
Schernberg A; Hennequin C
Cancer Radiother; 2017 Oct; 21(6-7):619-625. PubMed ID: 28774489
[TBL] [Abstract][Full Text] [Related]
19. Defining the "Hostile Pelvis" for Intensity Modulated Radiation Therapy: The Impact of Anatomic Variations in Pelvic Dimensions on Dose Delivered to Target Volumes and Organs at Risk in Patients With High-Risk Prostate Cancer Treated With Whole Pelvic Radiation Therapy.
Yirmibeşoğlu Erkal E; Karabey S; Karabey A; Hayran M; Erkal HŞ
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):894-903. PubMed ID: 26104941
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
